Prognostic and predictive value of endothelial dysfunction biomarkers in sepsis-associated acute kidney injury: risk-stratified analysis from a prospective observational cohort of pediatric septic shock.

Biomarkers Endothelial dysfunction Precision medicine Sepsis Sepsis-associated acute kidney injury Septic shock

Journal

Critical care (London, England)
ISSN: 1466-609X
Titre abrégé: Crit Care
Pays: England
ID NLM: 9801902

Informations de publication

Date de publication:
03 07 2023
Historique:
received: 10 05 2023
accepted: 28 06 2023
medline: 5 7 2023
pubmed: 4 7 2023
entrez: 3 7 2023
Statut: epublish

Résumé

Sepsis-associated acute kidney injury (SA-AKI) is associated with high morbidity, with no current therapies available beyond continuous renal replacement therapy (CRRT). Systemic inflammation and endothelial dysfunction are key drivers of SA-AKI. We sought to measure differences between endothelial dysfunction markers among children with and without SA-AKI, test whether this association varied across inflammatory biomarker-based risk strata, and develop prediction models to identify those at highest risk of SA-AKI. Secondary analyses of prospective observational cohort of pediatric septic shock. Primary outcome of interest was the presence of ≥ Stage II KDIGO SA-AKI on day 3 based on serum creatinine (D3 SA-AKI SCr). Biomarkers including those prospectively validated to predict pediatric sepsis mortality (PERSEVERE-II) were measured in Day 1 (D1) serum. Multivariable regression was used to test the independent association between endothelial markers and D3 SA-AKI SCr. We conducted risk-stratified analyses and developed prediction models using Classification and Regression Tree (CART), to estimate risk of D3 SA-AKI among prespecified subgroups based on PERSEVERE-II risk. A total of 414 patients were included in the derivation cohort. Patients with D3 SA-AKI SCr had worse clinical outcomes including 28-day mortality and need for CRRT. Serum soluble thrombomodulin (sTM), Angiopoietin-2 (Angpt-2), and Tie-2 were independently associated with D3 SA-AKI SCr. Further, Tie-2 and Angpt-2/Tie-2 ratios were influenced by the interaction between D3 SA-AKI SCr and risk strata. Logistic regression demonstrated models predictive of D3 SA-AKI risk performed optimally among patients with high- or intermediate-PERSEVERE-II risk strata. A 6 terminal node CART model restricted to this subgroup of patients had an area under the receiver operating characteristic curve (AUROC) 0.90 and 0.77 upon tenfold cross-validation in the derivation cohort to distinguish those with and without D3 SA-AKI SCr and high specificity. The newly derived model performed modestly in a unique set of patients (n = 224), 84 of whom were deemed high- or intermediate-PERSEVERE-II risk, to distinguish those patients with high versus low risk of D3 SA-AKI SCr. Endothelial dysfunction biomarkers are independently associated with risk of severe SA-AKI. Pending validation, incorporation of endothelial biomarkers may facilitate prognostic and predictive enrichment for selection of therapeutics in future clinical trials among critically ill children.

Sections du résumé

BACKGROUND
Sepsis-associated acute kidney injury (SA-AKI) is associated with high morbidity, with no current therapies available beyond continuous renal replacement therapy (CRRT). Systemic inflammation and endothelial dysfunction are key drivers of SA-AKI. We sought to measure differences between endothelial dysfunction markers among children with and without SA-AKI, test whether this association varied across inflammatory biomarker-based risk strata, and develop prediction models to identify those at highest risk of SA-AKI.
METHODS
Secondary analyses of prospective observational cohort of pediatric septic shock. Primary outcome of interest was the presence of ≥ Stage II KDIGO SA-AKI on day 3 based on serum creatinine (D3 SA-AKI SCr). Biomarkers including those prospectively validated to predict pediatric sepsis mortality (PERSEVERE-II) were measured in Day 1 (D1) serum. Multivariable regression was used to test the independent association between endothelial markers and D3 SA-AKI SCr. We conducted risk-stratified analyses and developed prediction models using Classification and Regression Tree (CART), to estimate risk of D3 SA-AKI among prespecified subgroups based on PERSEVERE-II risk.
RESULTS
A total of 414 patients were included in the derivation cohort. Patients with D3 SA-AKI SCr had worse clinical outcomes including 28-day mortality and need for CRRT. Serum soluble thrombomodulin (sTM), Angiopoietin-2 (Angpt-2), and Tie-2 were independently associated with D3 SA-AKI SCr. Further, Tie-2 and Angpt-2/Tie-2 ratios were influenced by the interaction between D3 SA-AKI SCr and risk strata. Logistic regression demonstrated models predictive of D3 SA-AKI risk performed optimally among patients with high- or intermediate-PERSEVERE-II risk strata. A 6 terminal node CART model restricted to this subgroup of patients had an area under the receiver operating characteristic curve (AUROC) 0.90 and 0.77 upon tenfold cross-validation in the derivation cohort to distinguish those with and without D3 SA-AKI SCr and high specificity. The newly derived model performed modestly in a unique set of patients (n = 224), 84 of whom were deemed high- or intermediate-PERSEVERE-II risk, to distinguish those patients with high versus low risk of D3 SA-AKI SCr.
CONCLUSIONS
Endothelial dysfunction biomarkers are independently associated with risk of severe SA-AKI. Pending validation, incorporation of endothelial biomarkers may facilitate prognostic and predictive enrichment for selection of therapeutics in future clinical trials among critically ill children.

Identifiants

pubmed: 37400882
doi: 10.1186/s13054-023-04554-y
pii: 10.1186/s13054-023-04554-y
pmc: PMC10318688
doi:

Substances chimiques

Biomarkers 0

Types de publication

Observational Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

260

Subventions

Organisme : NIDDK NIH HHS
ID : K23 DK119463
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001426
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM126943
Pays : United States
Organisme : NIH HHS
ID : KL2TR001426
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Crit Care. 2022 Jul 11;26(1):210
pubmed: 35818064
Crit Care Med. 2016 Nov;44(11):2010-2017
pubmed: 27513537
N Engl J Med. 2017 Jan 5;376(1):11-20
pubmed: 27959707
Pediatrics. 2010 May;125(5):1031-41
pubmed: 20421258
Crit Care. 2017 Aug 25;21(1):229
pubmed: 28841902
Am J Respir Crit Care Med. 2020 Apr 1;201(7):848-855
pubmed: 31916857
Semin Nephrol. 2015 Jan;35(1):2-11
pubmed: 25795495
Kidney Int. 2019 Nov;96(5):1083-1099
pubmed: 31443997
Clin J Am Soc Nephrol. 2008 Jul;3(4):948-54
pubmed: 18417742
Crit Care. 2020 Apr 15;24(1):150
pubmed: 32295614
Nat Rev Nephrol. 2017 Apr;13(4):241-257
pubmed: 28239173
Ann Intensive Care. 2019 Sep 11;9(1):103
pubmed: 31512003
Clin J Am Soc Nephrol. 2015 Aug 7;10(8):1324-31
pubmed: 26195505
Am J Respir Crit Care Med. 2019 Apr 1;199(7):863-872
pubmed: 30334632
JAMA. 2005 Aug 17;294(7):813-8
pubmed: 16106006
Sci Transl Med. 2019 Nov 13;11(518):
pubmed: 31723040
Am J Respir Crit Care Med. 2020 Aug 1;202(3):361-370
pubmed: 32101446
Intensive Care Med. 2009 May;35(5):871-81
pubmed: 19066848
Pediatr Crit Care Med. 2020 Sep;21(9):e686-e695
pubmed: 32569242
J Pediatr. 1997 Oct;131(4):575-81
pubmed: 9386662
Nat Rev Nephrol. 2020 Jan;16(1):20-31
pubmed: 31511662
Sci Rep. 2018 Jan 11;8(1):505
pubmed: 29323190
J Intensive Care. 2020 Dec 11;8(1):94
pubmed: 33308326
Pediatr Crit Care Med. 2005 Jan;6(1):2-8
pubmed: 15636651
Intensive Care Med. 2020 May;46(5):1050-1051
pubmed: 32047942
Crit Care Med. 2016 Dec;44(12):2241-2250
pubmed: 27513354
Crit Care Med. 2020 Oct;48(10):1513-1520
pubmed: 32769621
Crit Care. 2021 Feb 4;25(1):48
pubmed: 33541396
JAMA. 2019 May 28;321(20):1993-2002
pubmed: 31104069
Crit Care. 2016 Jul 03;20(1):207
pubmed: 27372077

Auteurs

Mihir R Atreya (MR)

Division of Critical Care Medicine, MLC2005, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. Mihir.Atreya@cchmc.org.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA. Mihir.Atreya@cchmc.org.

Natalie Z Cvijanovich (NZ)

UCSF Benioff Children's Hospital Oakland, Oakland, CA, 94609, USA.

Julie C Fitzgerald (JC)

Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.

Scott L Weiss (SL)

Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.

Michael T Bigham (MT)

Akron Children's Hospital, Akron, OH, 44308, USA.

Parag N Jain (PN)

Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.

Adam J Schwarz (AJ)

Children's Hospital of Orange County, Orange, CA, 92868, USA.

Riad Lutfi (R)

Riley Hospital for Children, Indianapolis, IN, 46202, USA.

Jeffrey Nowak (J)

Children's Hospital and Clinics of Minnesota, Minneapolis, MN, 55404, USA.

Geoffrey L Allen (GL)

Children's Mercy Hospital, Kansas City, MO, 64108, USA.

Neal J Thomas (NJ)

Penn State Hershey Children's Hospital, Hershey, PA, 17033, USA.

Jocelyn R Grunwell (JR)

Children's Healthcare of Atlanta at Egleston, Atlanta, GA, 30322, USA.

Torrey Baines (T)

University of Florida Health Shands Children's Hospital, Gainesville, FL, 32610, USA.

Michael Quasney (M)

CS Mott Children's Hospital at the University of Michigan, Ann Arbor, MI, 48109, USA.

Bereketeab Haileselassie (B)

Lucile Packard Children's Hospital Stanford, Palo Alto, CA, 94304, USA.

Matthew N Alder (MN)

Division of Critical Care Medicine, MLC2005, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.

Stuart L Goldstein (SL)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.
Division of Nephrology, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, OH, 45229, USA.

Natalja L Stanski (NL)

Division of Critical Care Medicine, MLC2005, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH